Clinical Trials Browser

Biosimilar Pharmaceuticals × 1 year × Clear all

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT06649331 2026-03-17

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07393425 2026-02-06

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT03564340 2025-12-03

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Phase 1/2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT07246317 2025-11-28

Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms

NCT05041842 2025-11-17

InTTercePT

Phase 2 Active not recruiting

Metastatic Breast Cancer With a Isolated Brain Progression

NCT07220135 2025-10-23

NeoTHERa

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06292286 2025-06-11

SCENIC

Phase NA Recruiting

Ovarian Neoplasms